1',2',3',4',5',6'-hexahydro-2'H-[2,4'-bipyridine] N-oxide | 279250-33-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1',2',3',4',5',6'-hexahydro-2'H-[2,4'-bipyridine] N-oxide
• 英文别名: 2-piperidin-4-ylpyridinium N-oxide；1',2',3',4',5',6'-hexahydro-[2,4']bipyridinyl 1-oxide；1-Oxido-2-piperidin-4-ylpyridin-1-ium
• CAS: 279250-33-8
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: HOLJFXDBTDNPBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1',2',3',4',5',6'-hexahydro-2'H-[2,4'-bipyridine] N-oxide 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 0.25h， 以96%的产率得到1',2',3',4',5',6'-hexahydro[2,4']bipyridinyl 1-oxide hydrochloride
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）化合物的组合物用于治疗性功能障碍。

  公开号：

  US20030229094A1
• 作为产物：
  描述：

  1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-carboxylic acid tert-butyl ester 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 1',2',3',4',5',6'-hexahydro-2'H-[2,4'-bipyridine] N-oxide
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）化合物的组合物用于治疗性功能障碍。

  公开号：

  US20030229094A1

文献信息

• Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
  申请人：Cowart D. Marlon

  公开号：US20060172995A1

  公开（公告）日：2006-08-03

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B, are as described in the specification.

  本发明涉及使用公式(I)化合物的用途，用于治疗性功能障碍，以及包含用于治疗性功能障碍的公式(I)化合物的组合物，其中A、L、D和B如说明书中所述。
• Oximes and hydrazones that are useful in treating sexual dysfunction
  申请人：Kolasa Teodzyj

  公开号：US20050176727A1

  公开（公告）日：2005-08-11

  The present invention relates to oximes and hydrazones of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及用于治疗性功能障碍的肟和腙的公式（I）化合物，以及含有用于治疗性功能障碍的公式（I）化合物的组合物。
• [EN] FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION<br/>[FR] COMPOSES AROMATIQUES BICYCLIQUES CONDENSES UTILES DANS LE TRAITEMENT DE DYSFONCTIONNEMENT SEXUEL
  申请人：ABBOTT LAB

  公开号：WO2003101994A1

  公开（公告）日：2003-12-11

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用化合物(I)的治疗性功能障碍，并涉及含有化合物(I)的组合物用于治疗性功能障碍。
• Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction
  申请人：Cowart D. Marlon

  公开号：US20070265249A1

  公开（公告）日：2007-11-15

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B 1 are as described in the specification.

  本发明涉及使用式（I）化合物治疗性功能障碍以及含有式（I）化合物的组合物治疗性功能障碍，其中A、L、D和B1如说明书所述。
• Discovery of 3-Methyl-<i>N</i>-(1-oxy-3‘,4‘,5‘,6‘-tetrahydro-2‘<i>H</i>-[2,4‘-bipyridine]-1‘-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D₄ Agonist for the Treatment of Erectile Dysfunction
  作者：Meena V. Patel、Teodozyj Kolasa、Kathleen Mortell、Mark A. Matulenko、Ahmed A. Hakeem、Jeffrey J. Rohde、Sherry L. Nelson、Marlon D. Cowart、Masaki Nakane、Loan N. Miller、Marie E. Uchic、Marc A. Terranova、Odile F. El-Kouhen、Diana L. Donnelly-Roberts、Marian T. Namovic、Peter R. Hollingsworth、Renjie Chang、Brenda R. Martino、Jill M. Wetter、Kennan C. Marsh、Ruth Martin、John F. Darbyshire、Gary Gintant、Gin C. Hsieh、Robert B. Moreland、James P. Sullivan、Jorge D. Brioni、Andrew O. Stewart

  DOI：10.1021/jm060662k

  日期：2006.12.1

  The goal of this study was to identify a structurally distinct D-4-selective agonist with superior oral bioavailability to our first-generation clinical candidate 1a (ABT-724) for the potential treatment of erectile dysfunction. Arylpiperazines such as (heteroarylmethyl) piperazine 1a, benzamide 2, and acetamides such as 3a,b exhibit poor oral bioavailability. Structure-activity relationship (SAR) studies with the arylpiperidine template provided potent partial agonists such as 4d and 5k that demonstrated no improvement in oral bioavailability. Further optimization with the (N-oxy-2-pyridinyl) piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a. The N-oxy-2-pyridinyl moiety not only provided the structural motif required for agonist function but also reduced metabolism rates. The SAR study leading to the discovery of 6b is described herein.